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KAJIAN GENETIK DOMAIN POKET A DAN B PADA GEN RB1 DI 
KALANGAN KANAK-KANAK RETINOBLASTOMA DI MALAYSIA 
 
ABSTRAK 
 
Retinoblastoma (RB) adalah sejenis kanser mata yang sering terjadi di kalangan kanak-
kanak yang berumur empat tahun dan ke bawah dengan kekerapan seorang pesakit di 
kalangan 15,000 hingga 20,000 kelahiran. Retinoblastoma berlaku dalam dua keadaan 
samada secara keturunan atau sporadik. Kanser mata yang boleh membawa maut ini 
memerlukan ketidakaktifan ke dua-dua alel pada gen penyekat tumor, RB1. Hasil 
penyelidikan terdahulu mendapati mutasi pada gen ini kebanyakkannya berlaku di 
kawasan domain poket A dan B. Tujuan penyelidikan ini adalah untuk mengenalpasti 
mutasi di kawasan domain poket A dan B pada gen RB1 dan kaitannya dengan fenotip 
klinikal pesakit retinoblastoma di Malaysia. DNA telah diekstrak daripada darah 50 
orang pesakit retinoblastoma dan 50 sukarelawan normal (kumpulan etnik yang sama 
dengan kumpulan pesakit) dengan menggunakan kit ekstrak darah komersial sebelum 
diamplifikasikan melalui kaedah tindakbalas berantai polimerase (PCR) pada ekson 12 
hingga 22 pada gen RB1 serta kawasan intron sekitarnya. Mutasi di dalam produk PCR 
disaring melalui teknik kromatografi cecair denaturasi berprestasi tinggi (DHPLC), yang 
kemudiannya disahkan dengan teknik penjujukan DNA. Didapati nisbah kanak-kanak 
lelaki kepada perempuan pesakit RB ialah 2:1 di mana 78% daripada pesakit adalah 
Melayu, 12% India dan 10% China. Leukocoria merupakan tanda klinikal awal pada 
sebahagian besar pesakit dan kebanyakkan melibatkan hanya sebelah mata sahaja. 
Secara purata, usia pesakit ketika diagnosa adalah 24.3 (16.9) [purata (SD)] bulan dan 
lebih awal iaitu dalam purata 19.47 (19.99) sekiranya kedua-dua belah mata dijangkiti 
xxi 
 
kanser. Setelah disaring, didapati 31 pesakit dan subjek kawalan mempunyai mutasi dan 
polymorphism nukleotida tunggal pada gen RB1. Semua mutasi adalah merupakan 
pertukaran nukleotida tunggal yang terletak di tujuh kawasan berbeza dalam jujukan 
intron dan juga di kawasan pemotongan intron-ekson. Dua mutasi baru juga telah 
ditemui iaitu IVS13+184C>T dan IVS17-133T>C di kalangan kumpulan pesakit dan 
kawalan. Walaubagaimanapun, tiada kaitan statistik yang signifikan ditemui antara 
semua variasi gen yang ditemui dengan fenotip klinikal pesakit. Namun, kaitan yang 
signifikan didapati antara IVS15-1G> A dan pesakit dari keturunan etnik China, serta 
IVS13+184 C> T, IVS17-133T> C dan IVS19-77A>G bagi kumpulan etnik yang 
berbeza dalam kumpulan kawalan. Berdasarkan penemuan ini, mutasi pada kawasan 
pemotongan intron-ekson iaitu IVS12+1G>A dan IVS15-1G>A mungkin memainkan 
peranan dalam mempengaruhi risiko seseorang untuk menghidap kanser ini. Sementara 
variasi lain mungkin mempunyai kepentingan sebagai penanda variasi genetik dalam 
populasi. Walaubagaimanapun, bilangan sampel yang lebih besar diperlukan bagi tujuan 
pengesahan. Sepanjang pengetahuan kami, ini merupakan laporan pertama mengenai 
mutasi pada kawasan intron domain poket A dan B dalam gen RB1 di kalangan pesakit 
retinoblastoma di Malaysia. Saringan pada keseluruhan gen RB1 adalah diperlukan bagi 
melengkapkan pengumpulan data genetik di Malaysia. 
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GENETIC STUDY OF POCKET A AND B DOMAIN OF RB1 GENE AMONG 
MALAYSIAN CHILDREN WITH RETINOBLASTOMA 
 
ABSTRACT 
 
Retinoblastoma (RB) is the most common intraocular tumor mainly affecting children 
under four years of age, with a prevalence of 1 in 15 000 to 20 000 live births. 
Retinoblastoma is divided into hereditary and non-hereditary types. The development of 
this malignancy requires both alleles of the tumor suppressor gene RB1 to be knocked-
out. Recent studies found mutation occurred more frequently in the pocket A and B 
domain of RB1 gene. The present study was undertaken to identify the mutation in the 
pocket A and B domain of RB1 gene among retinoblastoma patients in Malaysia, and 
the association of the mutation to the laterality and stage of the tumor. DNA was 
extracted from 50 RB patients and 50 healthy volunteers (ethnically matched to the 
patient group) blood using commercial blood mini kit prior to PCR amplification which 
was performed for exon 12 to 22 of RB1 gene and its intronic flanking region. The PCR 
products were screened for mutation through DHPLC analysis and sample with mutation 
was subjected to DNA sequencing analysis. The ratio of boy to girl patient were 2 : 1, 
where 78% were Malays, 12% Indian and 10% Chinese. Most of the patients presented 
with leukocoria and unilateral (only one eye affected) retinoblastoma. The mean age at 
diagnosis of patients is 24.3 (16.9) [mean (SD)] months with an earlier diagnosis among 
the bilateral cases [19.47(19.99)]. Thirty-one patient and control subjects presented with 
mutation and single nucleotide polymorphism (SNP), which then were identified as 
single nucleotide substitution which are located at seven distinct intronic regions, where 
two of the mutations affected splice site region. Two novel mutations were identified 
xxiii 
 
(IVS13+184C>T and IVS17-133T>C) in both patient and control group. No significant 
association was found either between mutations and laterality or stage of the tumor. 
Significant association was found between IVS15-1G>A and patient of Chinese origin, 
while IVS13+184C>T, IVS17-133T>C and IVS19-77A>G were found to be associated 
with different ethnic groups in the control group. We postulated that the splice site 
mutations, IVS12+1G>A and IVS15-1G>A might play a role in the predisposition to 
retinoblastoma, as shown by previous studies. The other five mutations and SNPs are 
probably important as genetic variant markers for population studies. However, a larger 
sample size is needed for confirmation. To the best of our knowledge, this is the first 
report of the mutations found within intronic region of pocket A and B domain of RB1 
gene among Malaysian children with retinoblastoma. In order to develop a more 
complete spectrum of RB1 mutations in Malaysian retinoblastoma patients, we suggest a 
larger scale of target screening region should be conducted in future research.  
1 
 
 
 
CHAPTER 1 
 
 
INTRODUCTION 
 
1.1   Retinoblastoma 
 
Retinoblastoma (RB), a form of childhood cancer, is the most common intraocular 
tumor of early childhood, which is usually diagnosed before the age of five (Devesa, 
1975). Generally, incidence of childhood cancer is less common than cancer in adult. 
It is present in less than 1% in industrialized country (Stiller and Draper, 2005). 
Nevertheless, childhood cancer has claimed the lives of many young children and is 
the second highest cause of death after road accident. The other most common 
childhood cancer is embryonic cancer (40%) such as acute leukemia, neuroblastoma, 
and Wilm tumor (Raja Khuzaiah, 1988). 
 
RB tumor arises from retinal cells, which line the back of the eye (Figure 1.1). 
Retina is composed of 10 layers, with the ganglion cells that lie innermost closest to 
the lens and front of eye, and photoreceptors that lay outer most of the retina (Figure 
1.2). The photoreceptor is composed of light-sensitive cells known as rods and cones. 
The photoreceptor is responsible for converting the light array into electro-chemical 
2 
 
signal that is later sent to the brain through the optic nerve, where they are turned 
into images.  
 
The formation of retina begins in the early stage of human development. Retinoblast, 
the infantile cells of retina were divided during mitosis and later developed to 
become mature retinal cells. After that, the development of new retinal cells just 
occurs to replace the old damaged retinal cells. However, sometimes the divisions of 
cells can be interrupted, thus affect the production of new cells. In RB disease, the 
production of new cells cannot be stopped although the body has sent the stop signals. 
Consequently, the cells keep on growing and multiplying, thus developing the retinal 
tumor. 
 
RB is caused by genetic mutation in a gene, known as retinoblastoma susceptibility 
gene (RB1 gene) in the retinal cells. RB1 gene is responsible to encode 
retinoblastoma phosphoprotein, (known as pRb protein), a regulatory protein that 
functions in cell cycle activity. pRb protein normally suppresses the cell cycle 
activity when the cell sends the signal to stop the production of new cells. Presence 
of mutation in RB1 gene is believed to be the main factor leading to loss of function 
of pRb protein in cell cycle activity by altering pRb structure, thus initiating the 
tumor development (Knudson, 1971; Lohmann, 1999). However, until now, the 
factors influencing the genetic changes in RB1 gene that caused RB still remains 
unclear. 
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Figure 1.1 : Schematic diagram of eye. Retinal cells located at back layer of the eye 
and connected with the optic nerve to transfer the light rays to electrical impulse and 
sent to the brain. (webvision.med.utah.edu/sretina.html) 
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Figure 1.2 : Schematic diagram of retinal layers. Ganglion cells located innermost 
closest to the lens of eye while photoreceptor, which contains rods, and cones lie 
outer most of retina. (webvision.med.utah.edu/sretina.html) 
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1.1.1 Clinical features of retinoblastoma 
1.1.1.1 Presenting signs and symptoms of retinoblastoma 
 
The most common presenting sign of RB is leukocoria or white reflex behind the 
pupil (Abramson et al., 1998), sometimes called cat eye’s reflex, which becomes 
obvious on exposure to certain light condition such as flash photography. The second 
most common sign is strabismus or also called crossed-eye. Strabismus develops as a 
result of interruption of the central fixation by the tumor. In most of the RB cases 
with sign of strabismus, half of the patients have crossed-in eye (esotropia) and half 
have crossed-out eye (exotropia) (Abramson et al., 1998). Although not all children 
with strabismus have retinoblastoma, fundus eye examination is essential to exclude 
the possibility of this disease. At advanced presentation, patients may present with 
sign of intraocular inflammation, with or without secondary glaucoma (Jerry and 
Carol, 2004). 
 
This tumor can also extend to other parts of the body. Extraocular extension may 
cause proptosis and involvement of adjacent structure such as the brain. Extraocular 
extension usually occurs relatively late. Two-thirds of extraocular extension cases 
occur by spreading of the tumor through optic nerve to the brain. The tumors also 
can grow through the sclera or spread via haematogeneous metastasis. Once the 
tumor reaches the brain or causing haematogenous spread, the cure is almost 
impossible (Schipper et al., 1985). Other signs of RB are severe pain in the affected 
eye, redness or irritation, and poor vision and blindness of the eyes. 
 
6 
 
Many reports have found the development of second nonocular tumor amongst RB 
patients. Abramson et al. (1976) reported that most of the second tumor is 
oesteosarcoma with range of incidence between 50% to 80%. Ninety seven percent 
of those with second tumor are patients with both eyes affected with tumor (bilateral 
RB).  
 
Tumors in retinal cells can invade and damage nearby tissue and organs. Tumor cells 
can travel to other parts of the body, growing and replacing normal cells and tissues. 
This process is called metastasis. In most neglected or untreated RB cases, the tumor 
can spread to extraocular parts, either through optic nerve (Magramm et al., 1989) or 
sclera (Rootman et al., 1978). Metastatic RB is usually found at regional lymph 
nodes, central nervous system (CNS), bone and bone marrow (Finger et al., 2002; 
Finger et al., 1999; Gunduz et al., 2006) as well as the ovaries (Darius et al., 2002). 
It has been reported that highest risk of developing metastatic RB occur among 
delayed diagnosed RB. 
 
1.1.1.2 Laterality of retinoblastoma 
 
RB can be unilateral or bilateral. Unilateral RB refers to one eye affected with the 
tumor, while bilateral RB refers to both eyes affected with this tumor. Most of RB 
patients presence with unilateral form, while less than 50% of RB cases are bilateral 
(Moll et al., 1997; Kayembe, 1986; Choy et al., 2002). In very rare cases (3%) 
patients are found with trilateral RB. Trilateral RB associated of bilateral RB with 
pinealoblastoma, the tumor of the brain. The commonest cause of death in RB is due 
to the intracranial extension (Hungerford et al., 1987; Melamud et al., 2006). 
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1.1.2 Inheritance characteristic of retinoblastoma 
 
RB can occur by transmission of the genetic changes from parents to their children 
(hereditary RB) or sporadically (non-hereditary RB). Hereditary and non-hereditary 
RB differs in many aspects including pattern of laterality, age of presentation and 
family history background 
 
Previous studies estimated around 40% of RB cases are germinal. Patients with 
germinal RB contained mutation in RB1 gene in all cells including the reproductive 
cells (sperm or ovum). They usually have a positive family history and have a high 
possibility to transmit the mutations to their offspring. Hereditary RB patients may 
inherit a copy of one abnormal allele of RB1 gene from one of the parent (Sorsby, 
1972) or alteration at one RB1 allele occur in sperm or ovum just after fertilization. 
The transmission of the altered allele or mutations in the RB1 gene occurs via 
autosomal dominant inheritance, with almost complete penetrance (85% to 95%) 
(Draper et al., 1992). Autosomal dominant inheritance means the mutation in the 
gene is located in one of the autosomes (chromosome 1 to 22). Therefore, both males 
and females have equal chance to develop this tumor. In this pattern of inheritance, 
single defective allele is sufficient for the individual to be affected by the disease.  
 
Developing of RB require mutation in both alleles of RB1 gene. Individual with 
hereditary RB inherited the first mutated allele from their parents and mutation of the 
second allele occurs somatically in the retinal cells in their lifetime (Knudson, 1971) 
(Figure 1.3). Parents who are carrying single defective copy of RB1 gene have 
higher chance of transmitting the gene, up to 50%. In some cases, mutations only 
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present in reproductive cells (either ovum or sperm) of the parents with RB, but 
without any mutation in somatic cells. This is known as gonadal mosaicism. If both 
parents carrying one copy of mutant alleles of RB1 gene, the possibility of 
transferring the mutated gene to their children become higher. Seventy-five percent 
(75%) of their children have risks of being affected with this disease and 25% to be 
more severe (Lohmann, 1999). 
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Figure 1.3: Mutational event among hereditary and non-hereditary (sporadic) RB. 
(a) In sporadic RB, both first and second mutations occur sporadically. (b) In 
hereditary RB, mutation in one allele is inherited from a parent and second mutation 
occur sporadically which will lead to tumor formation. 
(http://images2.clinicaltools.com/images/gene/cancer/knudson.gif) 
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Usually, hereditary RB patients develop this disease early in life (Knudson, 1971) 
and mostly affected both eyes. They are more likely to develop more than one 
independent tumor (multi focal) in one or both eyes. Germline mutations are also 
associated with increased risk of secondary tumor among the RB survivors. The most 
common secondary tumors are osteosarcoma (37.0%), other sarcoma (16.8%), 
melanomas (7.4%), brain tumor (4.5%), leukemia (2.4%), and non-Hodgkins 
lymphomas (1.6%) (Moll et al., 2001). Although most of hereditary RB is bilateral, 
almost 17% of the hereditary RB present with unilateral RB (Lohmann et al., 1997). 
 
In all of RB cases, 60% occurred sporadically. Most sporadic RB affect only one eye 
and presented at an older age than hereditary RB (Lohmann et al., 1997). In sporadic 
RB, mutation in both of RB1 alleles occurs sporadically and independently during 
somatic development of retinal cells. This may explain the late presentation of 
sporadic RB cases than hereditary RB because sporadic RB needs two mutational 
events while hereditary RB needs one more hit, as they already inherited one mutant 
allele. 
 
The triggering factor for somatic mutation is still unclear. Orjuela et al. (2000) 
suggest that papillomavirus (HPV) might play a role in RB since they found the 
sequences of this virus in RB tumor tissues. The environment factor might influence 
the development of this disease. More cases of RB have been found in less developed 
compared to developed country. 
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1.1.3 Staging of retinoblastoma 
 
Diagnosis of RB is done by several tests. It includes complete eye and funduscopic 
examination, where the pupil will be dilated so that the entire retina can be viewed 
and examined. In addition, the children also are examined through imaging studies 
such as computerized tomography (CT) scan and Magnetic Resonance Imaging 
(MRI). Imaging test provide detailed images of organs and structure within the eye. 
More over, confirmation of RB also can be done by molecular and cytogenetic 
screening tests (Chintagumpala et al., 2007; Melamud et al., 2006). 
 
Children confirmed with RB are then staged according to the presentation of the 
tumor. Staging is a process of finding out the location, size and extension of tumors. 
The stage of cancer is one of the important factors in choosing the appropriate 
effective treatment.  
 
There are three main classifications used for RB. It is Reese-Ellsworth Classification, 
Tumor-Nodal-Metastasize (TNM) Staging and International Classification of 
Retinoblastoma (ICRB). 
 
Reese and Ellsworth presented their suggestion on classification of RB at 67th 
Annual Meeting of American Academy of Ophthalmology (Reese and Ellsworth, 
1963). This classification, named as RE Classification, is the earliest staging system 
that has been evaluated for RB in early 1960s.  
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TNM Classification is a general cancer staging system used for malignant tumors. It 
describes the extent of cancer in patient’s body. TNM Classification has been 
developed by International Union Against Cancer (UICC) in order to provide a 
global standard staging system in classifying the spread of cancer in human body. 
TNM Classification are referred to T for tumor size, N for the involvement of 
regional lymph nodes and M for distant of metastasize.  
 
The current staging system for RB is International Classification of Retinoblastoma 
(ICRB) (Murphree, 2005). This classification gives guidelines for clinicians to 
choose the most appropriate treatment and might assist the prediction of the focal 
treatment and chemo reduction method (Table 1.1). The ICRB is more robust 
classification and was proposed for better prediction of successful treatment to 
preserve the globe and if possible maintaining the vision (Saleh, 2006). 
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Table 1.1 : International Classification of Retinoblastoma (ICRB) 
 
Group Features Treatment 
A Small tumor: <3 mm Cryotherapy, laser 
photocoagulation or 
transpuppillary 
thermotherapy 
 Large tumor: <3 mm 
B Macular: <3 mm to foveola 
Chemotherapy, Brach 
therapy or cryotherapy 
 Juxtapapillary: <3 mm to disc 
 Subretinal fluid: <3 mm from the margin 
 Focal seeds 
C Subretinal seeds: <3 mm 
Chemoreduction, 
chemotherapy, cryotherapy 
or brachytherapy 
 Vitreous seeds: <3 mm 
 Both subretinal and vitreous seeds: <3 mm 
 Diffused seeds 
D Subretinal seeds: >3 mm Chemo reduction, 
thermotherapy or low dose 
of external beam 
radiotherapy 
 Vitreous seed: >3 mm 
 Both subretinal and vitreous seeds: >3 mm 
E Extensive retinoblastoma occupying more 
than 50% or neovascular glaucoma or 
opaque media from hemorrhage in anterior 
chamber, vitreous or subretinal space 
Chemoreduction, 
thermotherapy, low dose of 
external beam radiotherapy 
or enucleation 
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1.1.4 Incidence of retinoblastoma 
 
Incidence of RB in the worldwide population range from 1 in 10,000 to 23,000 live 
births (Freedman and Goldberg, 1976; Sanders et al., 1988). In the United State (US), 
the mean incidences of RB over 30 years time (1975 to 2004) are 11.8 per million 
children before 4 years old. This number was stable for within that period with low 
variability of range (10.9 to 12.8 per million live births) (Broaddus et al., 2009). In 
other Northern America region such as Mexico, RB disease tends to be the second 
most common solid tumor among pediatrics patients after central nervous systems 
(CNS) tumor. Data from 16 Mexican centers from January 1997 to December 2002 
showed 83.3 new cases per year among children below 15 years old (Leal-Leal et al., 
2004). 
 
In European region, cumulative incidence of RB was found to be from 44.2 to 67.9 
per million live births. Data from Automated Childhood Cancer Infromation Systems 
(ACCIS) contains information of RB patients from 60 pediatrics and general centers 
from 1978 to 1997. It covered most of European country including British Isle, East, 
North, South and West region. Highest incidence occurs in the first year of life 
compared to other below 14 years old children (MacCarthy et al., 2006). 
 
In the Bantu of South Africa, data of RB cases shows high incidence number, 1 in 
10,000 live births. Higher cases were diagnosed among 2 to 3-year old children 
(Freedman and Goldberg, 1976). Numbers of RB in Africa are higher than other 
population such as Caucasoid population. More sadly, most of the cases end with 
death. 
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The incidence of RB in Japan and Singapore are quite similar. Both of this region 
reported 1 case in every 16 000 live births (Takano et al., 1991; Tan et al., 1997). 
98% of cases were found among children under 5 years old (Tan et al., 1997). In 
another Asian country such as Taiwan, the average annual incidence rate is 4.45 per 
million children under 10 years old and 8.58 per million children under 5 year old. 
The incidences of this disease have significantly increased from 1979 to 2003 (Chen 
et al., 2009). 
 
In Malaysia, the actual incidence of RB remains unclear. A report of RB cases 
among this population from 2001 to 2007 indicated that 105 cases have been 
reported to the medical centers with majority cases were diagnosed from 1 month to 
14 years old children (Menon et al., 2009). 
 
Most of RB cases are equally distributed among male and female patients (Menon et 
al., 2009; Leal-Leal et al., 2004; Kayembe, 1986). Although Freedman and Goldberg 
(1976) found distribution of RB cases with a male preponderance with male to 
female ratio of 2:1, the differences are not statistically significant. In contrast, 
Devesa (1975) found higher number of bilateral cases among female children with a 
ratio of 9: 1. The gender difference to the progression of RB remains unclear. 
 
In addition, higher mortality rate were found in blacks compared to whites. Incidence 
of RB in blacks and whites are 9.8 to 13.0 and 10.8 to 11.3 cases per million 
respectively. However, the differences of mortality rate between these two 
populations are not significant, thus excluding the contribution of ethnic race 
background in predisposition to RB tumor (Broaddus et al., 2009). 
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1.2 RB1 gene 
 
Retinoblastoma susceptibility gene or also known as RB1 gene is the first tumor 
suppressor gene and hereditary cancer gene to be cloned. In 1986, Friend et al. 
(1986) had isolated RB1 gene from long q arm of chromosome 13 at band 14.2 
(Figure 1.4). It consists of 27 exons ranging from 31-1873bp in size and 26 introns 
ranging from 80-70500bp. The whole gene is 180,388bp in size (Toguchida et al., 
1993). Promoter region of RB1 gene is located at 186-206bp upstream from initiation 
codon. It contains binding domain for various transcription factor protein such as 
RBF-1, Sp1, ATF and E2F (Ohtani-Fujita et al., 1993). The transcription of DNA by 
RNA polymerase is initiated at promoter region. The efficiency of DNA transcription 
varies by interaction between short regulatory DNA sequences within the promoter 
region with transcription factor proteins. Transcription factor is a large family of 
proteins that regulate the expression of the gene either positively or negatively. 
Transcription factor can increase or decrease the rate of transcription through 
interaction with the complex of protein including RNA polymerase (Winter et al., 
2002). The transcript of RB1 gene then transcribed to 4.7kb mRNA (messenger 
RNA). It comprised of 2.7kb open reading frame that encoded for a protein that 
contained 928 amino acids with molecular mass 110kDa. This protein is known as 
retinoblastoma phosphoprotein, pRb. 
  
The association of RB1 gene in developing tumor is not restricted to the RB only. 
Abnormalities of RB1 gene have also been found in other cancers such as 
osteosarcoma (Toguchida et al., 1988; Miller et al., 1996), breast cancer (Eyfjord and 
Thorlacius, 1992; Ceccarelli et al., 1998), acute leukemia (Sauerbrey et al., 1998; 
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Kornblau et al., 1998; Ahuja et al., 1991), bladder cancer (Grossman et al., 1998; 
Niehans et al., 1999), lung cancer (Otterson et al., 1994; Harbour et al., 1988) and 
other cancers (Sellers and Kaelin, 1997; Mutirangura et al., 1999). 
 
RB1 is a class of tumor suppressor gene. In this class of gene, both alleles need to be 
inactivated to allow the progression of tumor. Inactivation of one allele frequently 
occurs by point mutation and the second allele by deletion. 
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Figure 1.4 : Chromosome 13. RB1 gene located at long q arm at sub-band 14.2  
 (www.csmc.edu/csri/korenberg/int-bac-sts.html) 
 
 
 
 
 
 
 
 
 
 
19 
 
1.2.1 Retinoblastoma protein, pRb 
 
Since RB1 gene was identified as tumor suppressor gene, its encoded protein, pRb 
emerged as key regulator for cell cyle (Friend et al., 1986). Inactivation of pRb had 
been targeted by researchers in many studies of human cancer (Sherr, 1996; 
Weinberg, 1995). This phosphoprotein was found to bind with various endogenous 
nuclear proteins such as E2F transcription factor and tumor viral oncoprotein such as 
E1A adenovirus and human papillomavirus E7 (Whyte et al., 1988; Huang et al., 
1993). pRb protein normally play as negative regulator in the cell cycle (Kaelin, 
1999). In another study, pRb was found to control the chromatin structure during G1 
to S phase transition in cell cycle process (Isaac et al., 2006).  
 
Basically, pRb consist of four domains; N terminus, small pocket consists of A and B 
domain and C terminus (Figure1.5). Combination of small pocket A and B and part 
of C terminus make a complex which is known as large pocket domain (Harbour, 
1998). Pocket domain A and B play a critical role for pRb protein as transcription 
repressor by serving binding site for other proteins (Chow and Dean, 1996; 
Chellapan et al., 1991). In addition, frequent mutations have been identified within 
this region that is associated with non-functioning of pRb (Braggio et al., 2004; 
Lohmann, 1999). The other two N and C terminus were less studied, but it was 
believed to play specific role for pRb protein. Although no clear function was 
identified for N-terminus of pRb protein, some studies found interaction of pRb-
binding protein through this residue (Inoue et al., 1995). In a study by Xu et al. 
(1994), they suggested that N-terminal region of pRb protein may play a role in 
regulation of cell growth or differentiation-mediated by pRb protein. The C-terminus 
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is part of large pocket domain. It contains some domains that might be important for 
protein-protein interaction (Shew et al., 1990). One of the proteins that were found to 
bind to C-terminus domain is c-Abl tyrosin kinase, which latter might potentially 
regulate the transcriptional activity in S-phase of cell cyle (Welch and Wang, 1993). 
 
1.2.1.1   Pocket A and B domain of pRb protein 
 
The small pocket A and B pocket domain is the most conserved region in pRb 
protein. Domain A consists of amino acid 379 through 572 while domain B consists 
of amino acids 646 through 772. Both of these domains are separated by a 
nonconserved spacer region (Figure 1.5) (Harbour, 1998). Small pocket domains are 
sufficient and necessary for interaction with viral tumor protein such as simian virus 
40 large T antigens and adenovirus E1A (Kaelin et al., 1990). Both of domains A 
and B are required for transcriptional repression, but not the nonconserved separater 
region. Neither A nor B domain play the repression activity alone, but need both. 
One pocket domain is able to recruit the other domain to form repressor motif at the 
promoter, thus blocked the transcription (Chow and Dean, 1996). Mutations affect 
either A or B domain blocked the repression activity, signifying the importance and 
sufficiency of pocket domain for transcriptional repression (Dick and Dyson, 2002; 
Chow and Dean, 1996). Together with part of C-terminus domain, pocket A and B 
have ability to interact with E2F transcription factor and repress the transcription-
mediated by this protein (Chow and Dean, 1996). 
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Figure 1.5 : Structure of RB1 gene, mRNA transcript and pRb protein. Coloured 
boxes in mRNA transcript indicated the exons encoding for pocket A and B domain. 
*a.a refer to amino acids 
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The small pocket A and B of pRb binds to various nuclear proteins through two types 
of binding; binding involving LXCXE (L = leusine, C = cysteinc, E = glutamic acid, 
x = any amino acid) or non-LXCXE sequence–containing protein. Interaction 
involving LXCXE motif, a peptide sequence occur between pRb and several tumor 
viral proteins such as simian virus 40 large T antigen, adenovirus E1A and human 
papillomavirus E7 as well as endogenous protein such as HDAC1 and 2. Certain 
nuclear protein which lacks of LXCXE motif such as transcription factor E2F and 
C/EBP interact with pRb protein via non-LXCXE binding. Domain B carry LXCXE 
motif, while domain A play a role to activate the small pocket complexes (Audo and 
Sahel, 2003). 
 
1.2.2 pRb protein and cell cycle 
 
pRb regulates the tumor progression by preventing the cell cycle activity at G1 phase 
from entering S phase. In mammalian cells, the cell cycle are divided to 4 major 
division or phases; S phase, where the DNA are synthesized and replicated, M phase 
or mitotic phase where the chromosomes are divided into two nuclei in the mitosis 
process and 2 ‘gaps’; G1 and G2 phases. In the G1 and G2 phase, the cells are 
prepared for upcoming process in S and M phase respectively. In the resting cells, 
the cycle will stop by entering the G0 phase after mitotic phase. 
 
The role of pRb in cell cycle is basically related to their ability to bind with several 
nuclear proteins that can modulate their activities. Among these, the most studied 
nuclear protein that binds to pRb is transcription factor, E2F. The E2F-binding site 
have been found in several promoter sequence of growth promoting cellular genes 
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such as cyclin A, DNA polymerase alpha, cyclin D1, cdc2, c-myb, c-myc, tymidine 
kinase and E2F itself (Horowitz, 1993). Binding to pRb confiscate the transcription 
factor, which then blocked the E2F-mediated growth stimulation (Chellappan et al., 
1991;  Hiebert et al., 1992). 
 
Activation and inactivation of pRb are modulated by phosphorylation events which 
are controlled by complexes of cyclin-dependent kinases (CDKs) (Sherr, 1996; 
Wong and Weber, 2007). The pRb is active under hypophosphorylation and 
inactivated under hyperphosphorylation. The pRb inhibits the cell growth by binding 
to and repressing the activity of regulatory proteins including E2F transcription 
factor which is necessary for G1 to S phase transition. In the resting cells, pRb 
remains active until the cells are ready to divide. Phosphorylation of pRb in G1 phase 
by complexes of cyclin-dependent kinase (CDKs) and its cyclin partner inactives the 
pRb protein and reduce its ability to bind to E2F protein, thus allowing the 
progression of the cell. Phosphorylation of pRb is controlled by at least two distinct 
cyclin kinase complexes, D-type cyclins with cdk4/6 which then completed by cyclin 
E-cdk2 complexes (Lundberg and Weinberg, 1998). There are two distinct 
mechanisms of transcriptional repression by pRb protein. Transcriptional activity can 
be repress either by direct interaction between E2F transcriptional factor to the pRb 
binding site or by recruitment of chromatin-remodelling enzyme by pRb-E2F 
complexes (Poznic, 2009). Binding of E2F to pRb protein directly blocks the 
transcription-mediated E2F protein (Helin et al., 1993). Modifications of chromatin 
structure occur through histone acetylation (Felsenfeld, 1992). Complexes of 
repressor recruit histone deacetylases (HDACs) and form association with the 
complexes. This association inhibits the transcription by removing the acetyl groups 
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from histone core which then tighten the DNA and nucleosomes (Hasig et al., 1997; 
Siddiqui et al., 2003). 
  
1.2.3 Knudson two hits hypothesis 
 
In 1953, Carl O. Nordling, a scientist from Finland proposed the multi numbered of 
mutated genes in cancerous cells (Nordling, 1953). He also suggested that the 
accumulation of mutations might increase with age and cell proliferation rate, while 
the cell proliferation increased by exposure of the tissues to the mutatgens. His 
theory of multimutations in cancerous cells was supported by Ashley (1969), who 
suggested that cancer arises from 3 to 7 mutations depend on the different types of 
cancer. 
 
This theory then was formulated by a cancer geneticist, Alfred Knudson. In 1971, 
Knudson accidently observed different graph pattern of age on onset between two 
types of RB cases while studying the epidemiological data of RB patients. In his 
observation, he had found significant age of onset between hereditary and sporadic 
RB children. Hereditary cases more often diagnosed earlier than sporadic cases. In 
addition, most of hereditary disease have tumor in both eyes, suggesting underlying 
predisposition. In contrast, sporadic or non-hereditary RB have delay onset and most 
often occur unilaterally. Knudson hypothesized that multi mutations are necessary to 
initiate the tumor. In inherited RB, the first mutation is transmitted from parents via 
germ line cells and second mutations occur somatically, which later lead to tumor 
arises. In sporadic cases, two mutations have to take place before the tumor can 
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develop. This observation explains the differences of age of onset between inherited 
and sporadic RB.  
           
1.3 Spectrum of mutations in RB1 gene 
 
Mutations are defined as any changes or alteration of DNA sequences as a result of 
chemical or physical agent actions or rare errors in DNA replication (Winter et al., 
2002). Type of mutation can be classified according to their effect on DNA structure, 
function, inheritance or protein sequence. It can occur in a small or large scale. Small 
length mutation involved alteration of single nucleotide such as single nucleotide 
substitution, deletion or insertion, while larger scale mutation includes amplification 
or gene duplication, deletion part of chromosomes or loss of heterozygosity as a 
result of loss of one allele (Winter et al., 2002).  
 
Commonly mutations are classified based on their impact to the protein sequence. 
The types of mutation are missense, nonsense, frameshift and silent muatation. All 
types of mutation alter the protein sequence except silent mutation. Missense 
mutation usually occur at first and second nucleotide of codon (sequence of three 
nucleotide that encoded for an amino acid) sequence which later changed the amino 
acid and protein sequence as well. Nonsense mutations change the codon to 
termination codon, thus affecting the translation of mRNA transcript to end 
prematurely and produced shortened version of protein that lack part of its carboxyl-
terminal domain. These mutations give deleterious effect and always appear with 
mutant phenotype. Frameshift mutation occurs when extra base has been inserted or 
deleted from DNA sequences. If the insertion or deletion is not in triplet (sequence of 
